Irritable Bowel Syndrome

The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.

FODMAP

Gluten

Placebo

Uppsala University Hospital

Identification of IBS Metabotypes Based on Physiological Responses to Food

Molecular Phenotyping of IBS Subtypes

The questionnaire IBS-SSS will be used to monitor the IBS symptoms and relate it to how participants metabolically react to the diets (gluten, FODMAPS and control). The IBS-SSS will also be related to how the microbiota potentially could differentiate between individuals and how it can be related to the diets (gluten, FODMAPS and control).

Body weight (kg) and height (meters) will be combined to report BMI in kg/m^2. It will be related to IBS subtypes and how participants react on the diets (gluten, FODMAPS and control)

Blood pressure (mmHg) will be related to the IBS subtypes and how participants react on the diets (gluten, FODMAPS and control)

Heart rate (bpm) will be related to the IBS subtypes and how participants react on the diets (gluten, FODMAPS and control)

Data will be available after data base lock.

Per Hellström

Medical doctor, Professor

Uppsala University

Chalmers University of Technology

The study will be a double-blinded, randomized, placebo-controlled cross-over study.

The study will be double-blinded. Neither the participant nor the care providers or the outcome assessor will know which treatment is which.

Antibiotic Associated Diarrhea

Clostridium Difficile Associated Diarrhea

Enhanced Probiotic, one packet bid until 7 days after discontinuation of antibiotic

Go Live

Probiotics in Hospitalized Patients Study

Randomized Double-blind, Placebo-Controlled Trial Comparing the the Effect of Enhance Probiotic (EP, Go Live Rx,) Versus Placebo (Pl) on the Incidence of Clostridium Difficile Associated Diarrhea (CDAD) or Antibiotic-Associated Diarrhea (AAD)in Hospitalized Patients Initiated on Antibiotics

papillon-lefevre disease/diaree

Identification of IBS Metabotypes Based on Physiological Responses to Food

Probiotics in Hospitalized Patients Study

Cea mai completă bază de date cu plante medicinale susținută de știință